Malignant hyperthermia
Drug Safety Update
December 2014: Intravenous dantrolene: risk of undissolved crystals
Important safety information
Dantrolene should only be administered by, or under the direct supervision of, personnel experienced in the use of dantrolene when used for malignant hyperthermia
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary